Pluristem Therapeutics Announces Interim Results from PLX-PAD Clinical Trials
News Jan 14, 2010
Pluristem Therapeutics Inc. has announced interim results from their Phase I clinical trials utilizing their placenta derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). Data suggested that PLX-PAD is safe and potentially efficacious.
“We are encouraged by the consistency of the data and believe that PLX-PAD may be an effective treatment for CLI.”
Nine patients, representing one-third of the patients needed to complete the Phase I dose-escalating studies in the U.S. and Germany, have been dosed with PLX-PAD. Patients experienced no significant unfavorable effects related to PLX-PAD administration. Three of the nine patients dosed completed their three-month follow up and the data from those patients demonstrated a trend towards efficacy with a reduction in their Rutherford Category, a measure of the severity of their limb ischemia.
“The interim results are in line with the data from the first patient treated with PLX-PAD,” said Professor Doctor André Schmidt-Lucke, Director of the Franziskus-Krankenhaus Institute of Berlin, Germany. “We are encouraged by the consistency of the data and believe that PLX-PAD may be an effective treatment for CLI.”
Zami Aberman, chairman and CEO of Pluristem, added, “The interim results are a significant milestone for Pluristem as we advance in our Phase I clinical trials to further test the safety and potential efficacy of PLX-PAD.”
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019